Other research analysts also recently issued reports about the stock. HC Wainwright restated a buy rating and issued a $19.00 target price on shares of Celldex Therapeutics in a research note on Monday, November 11th. Zacks Investment Research raised shares of Celldex Therapeutics from a hold rating to a buy rating and set a $2.25 price target on the stock in a research note on Wednesday, October 9th.
Celldex Therapeutics stock opened at $2.53 on Tuesday. The firm has a market capitalization of $38.71 million, a PE ratio of -0.37 and a beta of 3.42. Celldex Therapeutics has a one year low of $2.01 and a one year high of $11.63. The stock’s 50 day moving average price is $2.37 and its 200 day moving average price is $2.43. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.32 and a current ratio of 6.32.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Morgan Stanley lifted its stake in shares of Celldex Therapeutics by 372.1% in the second quarter. Morgan Stanley now owns 11,132 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 8,774 shares in the last quarter. HighTower Advisors LLC purchased a new stake in Celldex Therapeutics during the 2nd quarter worth approximately $31,000. Wedbush Securities Inc. purchased a new stake in Celldex Therapeutics during the 2nd quarter worth approximately $36,000. Virtu Financial LLC purchased a new stake in Celldex Therapeutics during the 3rd quarter worth approximately $30,000. Finally, A.R.T. Advisors LLC raised its position in shares of Celldex Therapeutics by 70.1% in the 2nd quarter. A.R.T. Advisors LLC now owns 52,741 shares of the biopharmaceutical company’s stock valued at $141,000 after purchasing an additional 21,741 shares in the last quarter. 24.50% of the stock is currently owned by institutional investors and hedge funds.
Celldex Therapeutics Company Profile
Celldex Therapeutics, Inc engages in the research, development, and commercialization of immunotherapies and other targeted biologics. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379.
Featured Story: Does the discount rate affect the economy?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.